Student Spotlight: Analyzing cancer therapeutics

Anne-Marie Feeney is a data analyst at the Stanford Cancer Institute who is applying skills from Brown's new online master’s degree in biostatistics and health data science to her cutting-edge work in CAR-T cell therapy.

We have access to more biological and health-related data than ever before. In public health practice and research, biostatisticians step in to make sense of it, analyzing data to gain insights, testing ideas and applying findings to real-world problems. Their work ensures that medical and public health professionals can make decisions based on the strongest evidence. 

In the spring of 2025, the Department of Biostatistics in Brown’s School of Public Health launched a fully online version of the school’s traditional Master’s in Biostatistics program: the Online Sc.M. in Biostatistics and Health Data Science. The new program provides rigorous training in biostatistical methods to help students meet the growing demand for leaders in the field. There are currently 28 students enrolled in Brown's online biostatistics Sc.M., with the very first cohort expected to graduate in the Summer of 2026.

Among this inaugural class is Anne-Marie Feeney. A data analyst in the Center for Cancer Cell Therapy at the Correlative Science Unit of the Stanford Cancer Institute, Feeney manages and analyzes assay data, such as flow cytometry and qPCR. Essentially, she is working to quantify CAR-T cells, or genetically engineered immune cells used in immunotherapy, and to track how those cells expand over time.

A native of Lexington, Massachusetts, Feeney studied math and economics at Georgetown University before working at the Dana-Farber Cancer Institute in Boston. We caught up with the recent West Coast transplant to learn more about her work and how Brown’s newest degree program is impacting her research.

You’re working on cutting-edge cancer research at Stanford. What motivated you to pursue an online degree at Brown?

My main motivation in pursuing a degree was to strengthen my coding skills and to build more public health and biology knowledge, since my undergraduate degree was in math and economics. I actually started out in Brown’s online MPH program and really enjoyed it, but I needed a program with a stronger focus on coding. When I learned that the Health Data Science program was launching, I transferred.

What appealed to me about this program was the opportunity to learn how to integrate coding with advanced statistical modeling techniques, domain knowledge, and communication - the skills needed to make defensible decisions from real-world data. What I love is that I can learn something in class, and immediately apply it to my work.

I also liked that Brown’s online MPH program allowed me to keep working full-time. Even after moving to the West Coast, where the live sessions often overlap with work hours, all the materials are available on Canvas, and there’s a strong sense of community. 

What I love is that I can learn something in class, and immediately apply it to my work.

Anne-Marie Feeney Data analyst at the Stanford Cancer Institute and GS
 
Anne-Marie Feeney

How do you balance your research with your studies?

I take the program part-time, so it’s very manageable. Most of my coursework happens at night or on weekends. Time management is the biggest strategy—sometimes it means saying no to social plans so I can finish a problem set or prepare for a midterm, but overall, it’s definitely doable.

Tell us about how advanced biostatistical methods and data science are used in cancer research?

Cancer and public health data can be noisy and heterogeneous, so good data management and advanced methods are essential. For example, a lot of basic statistics assumes independent samples, but with cancer data, you might have multiple samples from the same patient. You need multilevel models that account for both within-patient and between-patient variability.

Beyond that, AI is transforming drug discovery. What used to take years—like identifying promising molecules—can now sometimes be done in days. I don’t work directly in that area, but I strongly believe in using AI responsibly to accelerate discoveries that can help patients.

How are the skills you’re gaining in data science impacting your work now?

In my first class, Statistical Programming for Health Data Science, we focused on ggplot2 in R, which is a tool for data visualization. I’d already been using it in my work at Stanford, but the class helped me to build a stronger foundation, knowing which plots to use and why.

Now I apply that directly to my job, whether it’s generating reports or visualizing how CAR-T cells expand in patients over time. 

What are your post-graduate plans?

Long term, I’d like to become a director of data science in the cancer field. That would allow me to choose projects with the greatest impact on patients.

In my current group, for example, we support many trials, including one on a rare pediatric brain cancer, which is extremely difficult to treat. If AI can help identify promising molecules that lead to new therapies, that could be game-changing. That’s the kind of work that motivates me to keep going, in both my research and my studies.